Response to Comments on “Diagnosis and Management of Osteoporosis of the Jaw: A Systematic Review and International Consensus”

Abstract

Additionally in [1], the title of the article listed in reference number 8 was misspelled. The correct title for reference number 8 is as follows.Peters E, Lovas GL, Wysocki GP. Lingual mandibular sequestration and ulceration.

Oral ulceration with bone sequestration: Retrospective study of eight cases and literature review

“…The cases described herein presented with an oral ulcer covering a bone sequestrum at sites of bone prominence, in the absence of any known cause of osteonecrosis, features consistent with OUBS (Gadiwalla & Patel, ; Khan, Morrison, Ruggiero, et al, ; Palla et al, ). Although OUBS has no pathognomonic microscopic characteristics (Farah & Savage, ), histopathological examination confirmed the presence of necrotic bone.…”

“…Oral ulceration with bone sequestration (OUBS) designates a site‐specific oral ulcer that covers exposed, non‐vital bone in patients lacking any etiological factor known to induce osteonecrosis (Gadiwalla & Patel, ; Khan, Morrison, Ruggiero, et al, ; Palla, Burian, Klecker, Fliefel, & Otto, ). It has been reported in the literature under various descriptive names (Otto et al, ; Palla et al, ), including lingual mucosal ulceration with mandibular sequestration (Dhanrajani, ; Jackson & Malden, ), lingual mucosal ulceration with bone necrosis (Alkabouli, Kokovic, & Emad, ), lingual mandibular bone sequestration (Gündüz, Özden, Kurt, Bulut, & Günhan, ), lingual mandibular sequestration and ulceration (Peters, Lovas, & Wysocki, ), lingual mandibular sequestration with ulceration (Kessler, ), lingual mandibular osteonecrosis (Cerruto, Ugolini, & Cozzani, ), oral ulceration with mandibular necrosis (Villa & Gohel, ), oral ulceration with bone sequestration (Carrard, Sieck, Chaves, Filho, & Rados, ; Farah & Savage, ; Palla et al, ), mandibular bone exposure and osteonecrosis (Kharazmi et al, ), bone sequestration (Friel & Macintyre, ), bony necrosis and sequestration in the mandible (Fisher, ), spontaneous alveolar bone sequestration (Danesh‐Meyer, ), idiopathic exposure and sequestration of alveolar bone (Sonnier & Horning, ), oral ulceration (Scully, ), or osteonecrosis (Almazrooa, Chen, Nascimben, Woo, & Treister, ; Gabric, Seiwerth, Baraba, Vucicevic & Boras, 2017; Kharazmi, Nilsson, & Hallberg, ).…”

“…The clinicopathological features of OUBS are not thoroughly described in the literature, and the need for additional well‐documented cases has been previously emphasized (Fisher, ; Khan, Morrison, Ruggiero, et al, ; Palla et al, ). We aimed to conduct a retrospective study of eight new cases of OUBS and to provide a detailed review of the English literature on this pathologic entity.…”

Cancer Treatment–Induced Bone Loss and Role of Denosumab in Nonmetastatic Prostate Cancer: A Narrative Review

“…However, treatment with intravenous (IV) zoledronic acid requires hospital visits once every few months (range: 3–12 months) which puts the patients on burden for travel, waiting, set up, and monitoring time, and a 15-minute infusion time. 37 38 Need for intravenous access and administration, regular requirement of renal function monitoring with necessary dose adjustments, and treatment of renal damage caused in patients during the therapy are some other challenges with zoledronic acid treatment. 37 38 Denosumab treatment does not have these limitations, given subcutaneously.…”

“…37 38 Need for intravenous access and administration, regular requirement of renal function monitoring with necessary dose adjustments, and treatment of renal damage caused in patients during the therapy are some other challenges with zoledronic acid treatment. 37 38 Denosumab treatment does not have these limitations, given subcutaneously. It does not require renal function monitoring/dose modifications or hospitalization for drug administration.…”